Results 161 to 170 of about 9,558 (217)
Some of the next articles are maybe not open access.
Drugs, 2012
Rilpivirine is an orally administered, non-nucleoside reverse transcriptase inhibitor that is a component drug in combination therapy for antiretroviral-naive patients with HIV-1 infection. The randomized, double-blind, double-dummy, multinational ECHO and THRIVE trials in antiretroviral-naive adult patients with HIV-1 infection compared rilpivirine ...
exaly +3 more sources
Rilpivirine is an orally administered, non-nucleoside reverse transcriptase inhibitor that is a component drug in combination therapy for antiretroviral-naive patients with HIV-1 infection. The randomized, double-blind, double-dummy, multinational ECHO and THRIVE trials in antiretroviral-naive adult patients with HIV-1 infection compared rilpivirine ...
exaly +3 more sources
Dolutegravir–rilpivirine coformulation
Current Opinion in HIV and AIDS, 2018With prolonged life expectancy in HIV-positive patients on combination antiretroviral therapy, the quest for reducing lifelong drug exposure and minimizing or avoiding the toxicities of combination antiretroviral therapy while maintaining viral suppression has emerged when coformulations of antiretroviral agents with improved convenience, and better ...
Hsin-Yun, Sun +2 more
openaire +2 more sources
Chirality, 2018
AbstractNuclear magnetic resonance (NMR) technique has been used to find the property of atropisomerism in Rilpivirine hydrochloride by variable temperature analysis and various 2D techniques. Both the Rilpivirine hydrochloride (E‐isomer) and Impurity‐A (Z‐isomer) isomers have been differentiated and confirmed by NMR and ultraviolet techniques ...
Senthilkumar Natarajan +4 more
openaire +2 more sources
AbstractNuclear magnetic resonance (NMR) technique has been used to find the property of atropisomerism in Rilpivirine hydrochloride by variable temperature analysis and various 2D techniques. Both the Rilpivirine hydrochloride (E‐isomer) and Impurity‐A (Z‐isomer) isomers have been differentiated and confirmed by NMR and ultraviolet techniques ...
Senthilkumar Natarajan +4 more
openaire +2 more sources
Cabotegravir Plus Rilpivirine: First Approval
Drugs, 2020A regimen comprising extended release injectable suspensions of cabotegravir and rilpivirine for concurrent administration (CABENUVA™) is being developed by ViiV Healthcare and Janssen Pharmaceutica (Janssen) as a complete regimen for HIV infection. Based on the results of the ATLAS and FLAIR trials, the regimen was recently approved in Canada for the ...
openaire +2 more sources
Boceprevir, telaprevir, and rilpivirine hydrochloride
Journal of the American Pharmacists Association, 2012Antiviral agents Agents for hepatitis C virus infection Hepatitis C virus (HCV) infection is characterized by inflammation of the liver, which can lead to reduced liver function and liver failure. The infection can develop in a number of ways, including exposure to blood that is infected with the virus, being born to a mother with HCV, having a sexual ...
Daniel A, Hussar, Clayton W, Snell
openaire +2 more sources
[Resistance profile of rilpivirine].
Enfermedades infecciosas y microbiologia clinica, 2015Rilpivirine (RPV) is a new second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) approved for use in combination with two nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) as initial therapy in treatment-naïve HIV-1-infected patients with a baseline viral load ≤100,000 copies/mL.
Arkaitz, Imaz +3 more
openaire +2 more sources
Long-acting rilpivirine for HIV prevention
Current Opinion in HIV and AIDS, 2015Long-acting injectable antiretroviral (ARV) formulations are being developed for the treatment and prevention of HIV infection. The purpose of this review is to summarize recent preclinical and clinical data on TMC278 (rilpivirine), a nonnucleoside reverse transcriptase inhibitor (NNRTI), that is being developed for both a treatment and prevention ...
Akil, Jackson, Ian, McGowan
openaire +2 more sources